New pill combo shows promise in halting Hormone-Fueled breast tumors

NCT ID NCT05607004

Ongoing Disease control Sponsor: Atossa Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop estrogen-driven breast cancer growth in premenopausal women. About 87 participants will take the drugs for up to 24 weeks before surgery. The main goal is to see if the treatment reduces a key tumor growth marker (Ki-67) or shrinks the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer Her2-receptor negative breast cancer invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER HER2-NEGATIVE BREAST CANCER INVASIVE BREAST CANCER

Contacts and locations

Locations

Avera Cancer Institute

Sioux Falls, South Dakota, 57105, United States
Baylor University

Houston, Texas, 77054, United States
Bon Secours Cancer Institute

Midlothian, Virginia, 23114, United States
California Research Institute

Los Angeles, California, 90027, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Henry Ford Cancer Institute

Detroit, Michigan, 48202, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Northwestern University

Chicago, Illinois, 60611, United States
St. Elizabeth Healthcare

Edgewood, Kentucky, 41017, United States
University of Arizona

Tucson, Arizona, 85719, United States
Vanderbilt Ingram Cancer Center

Nashville, Tennessee, 37204, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.